Strategic Partnerships DiaSorin’s distribution agreement with McKesson signals a strong channel for Luminex products; explore co-selling opportunities, leverage McKesson's clinical network for Luminex diagnostics and research solutions.

CE Mark Growth Upcoming and recent CE-marked launches such as LIAISON QuantiFERON-TB Gold Plus II indicate demand for high-throughput, regulatory-compliant assays; target laboratories expanding infectious disease testing and TB screening.

Targeted Markets Luminex serves clinical diagnostics, pharma discovery, genomics/proteomics, and food safety; identify cross-sell where labs require integrated platforms spanning research to clinical workflows.

Expansion Signals Recent product introductions and regional hires suggest growth momentum; position solutions for labs scaling operations, increasing throughput, and upgrading to versatile multiplexed workflows.

Platform Synergy Tech stack and enterprise tools indicate a mature IT footprint; present value through seamless integrations with existing ERP, CRM, and lab information systems to shorten procurement cycles.